Loading
Deliberately not treating a cancer yet, but checking it regularly with blood tests, scans or biopsies and treating only if it shows signs of progressing. Standard for low-risk prostate cancer, small kidney masses and several other slow conditions.
Active surveillance avoids or defers the harms of treatment for cancers unlikely to cause trouble: Grade Group 1 prostate cancer (ProtecT showed no survival penalty at 15 years), small renal masses, papillary thyroid microcarcinoma, low-risk DCIS (COMET), smouldering myeloma and early-stage CLL, and stage I testicular cancer after orchiectomy. It differs from watchful waiting, which forgoes curative intent. 'Surveillance' also describes the scheduled follow-up after curative treatment (CT, ctDNA, MRI in small-cell lung cancer instead of prophylactic cranial irradiation), and after complete response in organ-preservation strategies (SANO in oesophageal cancer).
Shares Percentage of Gleason pattern 4, PSA density, PIVOT (Prostate Cancer Intervention Versus Observation Trial), SPCG-4 (Scandinavian Prostate Cancer Group Study 4).
Shares Padeliporfin, Focal and tissue-preserving treatment of prostate cancer, ProtecT, Prostate cancer.
Shares PIVOT (Prostate Cancer Intervention Versus Observation Trial), SPCG-4 (Scandinavian Prostate Cancer Group Study 4), Choosing treatment for localised prostate cancer: what each option costs, ProtecT.
Shares Percentage of Gleason pattern 4, PIVOT (Prostate Cancer Intervention Versus Observation Trial), SPCG-4 (Scandinavian Prostate Cancer Group Study 4), Focal and tissue-preserving treatment of prostate cancer.
Shares Oncotype DX Genomic Prostate Score, Prolaris, Active surveillance, Prostate cancer.
Shares Percentage of Gleason pattern 4, Cribriform growth pattern in prostate cancer, Gleason score / Grade Group, Prostate cancer.
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
Shares PSA density, PSA kinetics: PSA doubling time and PSA density, Active surveillance, Prostate cancer.